
    
      The purpose of this Phase IIa/IIb dose ranging study is to generate human data in the
      intended patient population with IgAN to establish clinical proof-of-concept and to evaluate
      dose responses to support dose selection for subsequent clinical development of LNP023 for
      IgAN and potentially other indications
    
  